Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.48 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.43 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.43 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6095119 | 0.88 | TSHR (0.58) | KDM4EHPGDMTNR1AMTNR1BALOX5 | |
| SCHEMBL15595763 | 0.88 | ALOX5 (0.49) | KDM4EMTNR1AMTNR1BALOX5FAAH | |
| SCHEMBL153056 | 0.84 | CA12 (0.59) | KDM4ETSHRMAPTLMNATUBB4A | |
| SCHEMBL2729632 | 0.82 | TSHR (0.64) | KDM4ETSHRMAPTSMN1; SMN2PTGS1 | |
| SCHEMBL27200118 | 0.81 | KDM4E (0.45) | KDM4EMTNR1AMTNR1BALOX5MAPT | |
| SCHEMBL13186099 | 0.79 | KDM4E (0.45) | KDM4EHSD17B10HPGDMTNR1AMTNR1B | |
| SCHEMBL27836392 | 0.79 | KDM4E (0.53) | KDM4EALOX5MAPTLMNATUBB4A | |
| SCHEMBL6615190 | 0.79 | KDM4E (0.54) | KDM4EMTNR1AMTNR1BTSHRMAPT | |
| SCHEMBL19225758 | 0.79 | NPC1 (0.48) | KDM4EHPGDMTNR1AMTNR1BMAPT | |
| SCHEMBL4627636 | 0.78 | NPC1 (0.60) | KDM4EHPGDMTNR1AMTNR1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | Janssen Biopharma, Inc. | 2017-10-05 | — | — | US | disclosed |
| US-9724351-B2 | Compounds for the treatment of paramoxyvirus viral infections | ALIOS BIOPHARMA, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2015-08-27 | — | — | US | disclosed |
| EP-0054924-B1 | PHARMACEUTICAL COMPOUNDS, THEIR PREPARATION AND USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1986-08-06 | — | — | EP | disclosed |
| US-4535183-A | PALLIATION OF SICKLE CELL ANEMIA, RESPIRATORY DISORDERS, HYPOXIA, RADIOSENSITIZATION OF TUMORS | BURROUGHS WELLCOME CO. (US) | 1985-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150238498-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMOXYVIRUS VIRAL INFECTIONS | SARS1, MAVS, ZC3HAV1 | KDM4E 3296/4885HSD17B10 3484/4885HPGD 2567/4885 |
| US-20170283429-A1 | COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS | MAVS, SARS1, ZC3HAV1 | KDM4E 3430/4885HSD17B10 3992/4885HPGD 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.